Intravail™: Highly effective intranasal delivery of peptide and protein drugs

Expert Opinion on Drug Delivery

Volumn 3, Issue 4, 2006, Pages 529-539

  Maggio, Edward T ^a  

^a Aegis Therapeutics LLC   (United States)

Author keywords

Absorption enhancers; Intranasal delivery; Intravail ; Nasal insulin; Non invasive drug delivery; Peptide drugs; Protein drugs; Systemic drug delivery; Therapeutic peptides; Therapeutic proteins; Transmucosal delivery

Indexed keywords

DEOXYSUGAR; DRUG; DRUG CARRIER; PEPTIDE; PROTEIN;

ADSORPTION; ANIMAL; ARTICLE; BIOAVAILABILITY; DRUG EFFECT; HUMAN; INTRANASAL DRUG ADMINISTRATION; METABOLISM; METERED DOSE INHALER; NOSE MUCOSA;

ADMINISTRATION, INTRANASAL; ADSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; DEOXY SUGARS; DRUG CARRIERS; HUMANS; METERED DOSE INHALERS; NASAL MUCOSA; PEPTIDES; PHARMACEUTICAL PREPARATIONS; PROTEINS;

EID: 39049193678     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.4.529     Document Type: Review

References (58)

1. DEFRONZO RA, RATNER RE, HAN J et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care (2005) 28(5):1092-1100. (Pubitemid 40616618)
2. BATTERHAM RL, COWLEY MA, SMALL CJ et al.: Gut hormone PYY(3-36) physiologically inhibits food intake. Nature (2002) 418(6898):650-654. (Pubitemid 34886868)
3. GRASSO P, ROZHAVSKAYA-ARENA M, LEINUNG MC, LEE DW: [D-LEU-4]-OB3, a synthetic leptin agonist, improves hyperglycemic control in C57BL/6J ob/ob mice. Regul. Pept. (2001) 101(1-3):123-129. (Pubitemid 32728378)
4. PATTON JS, BOSSARD MJ: Drug delivery strategies for proteins & peptides from discovery & development to life cycle management. Drug Delivery Technology (2004) 4(8):44.
5. SEHGAL A: Peptides: markets and trends. In: Peptide Therapeutics - Applications in the Treatment of Human Disease. D&MD Publications, Westborough, MA, USA (2004):Chapter 2.
6. DEVILLERS G: Exploring a pharmaceutical market niche & trends: nasal spray drug delivery. Drug Delivery Technology (2003) 3(3):48.
7. BOMMER R: Drug delivery - nasal route. In: Encyclopedia of Pharmaceutical Technology. J Swarbrick, JC Boylan (Eds), Dekker Encyclopedias, New York, NY, USA (2002):854-862. • Provides a broad and representative introduction to intranasal delivery from the a theoretical as well as a practical perspective.
8. HUSSAIN AA: Intranasal drug delivery. Adv. Drug Del. Rev. (1998) 29:39-49. (Pubitemid 28044085)
9. LOGEMANN CD, RANKIN LM: Newer intranasal migraine medications. Am. Fam. Physician (2000) 61(1):180-186. (Pubitemid 30048849)
10. AHSAN F, ARNOLD J, MEEZAN E, PILLION DJ: Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm. Res. (2001) 18:1742-1746. (Pubitemid 34020431)
11. PARMAR H: Strategic Analysis of the Therapeutic Peptides Market in Europe. Frost & Sullivan, San Antonio, TX, USA (2004) Chapter 2, Section 4.
12. PILLION DJ, HOSMER S, MEEZAN E: Dodecylmaltoside-mediated nasal and ocular absorption of lyspro-insulin: independence of surfactant action from peptide multimer dissociation. Pharm. Res. (1998) 15:1641. (Pubitemid 28465753)
13. ARNOLD JJ, AHSAN F, MEEZAN E, PILLION DJ: Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J. Pharm. Sci. (2004) 93:2205-2213. •• This paper describes the comparative performance of a number of alkylsaccharides and presents electron and fluorescence micrographic data, shedding light on the likely mechanism of action.
14. WERMELING DP, MILLER JL, RUDI AC: Systematic intranasal drug delivery: concepts and applications. Drug Delivery Technology (2002) 2(1):56-61. • Provides a broad and representative introduction to intranasal delivery from the theoretical as well as the practical perspective.
15. MYGIND N, ANGGARD A: Anatomy and physiology of the nose-pathophysiology alterations in allergic rhinnitis. Clin. Rev. Allergy (1984) 2:173-188.
16. ILLUM L: Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. (2000) 11:1-18. (Pubitemid 30410839)
17. BEHL CR, PIMPLASKAR HK, SILENO AP, DEMEIRELES J, ROMEO VD: Effects of physiochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Delivery Rev. (1998) 29:89-116. • This paper also provides a broad and representative introduction to intranasal delivery from the theoretical as well as the practical perspective.
18. DJUPESLAND PG, SKRETTING A, WINDEREN M, HOLAND T: Bi-directional nasal delivery of aerosols can prevent lung deposition. J. Aerosol Med. (2004) 17(3):249-259. (Pubitemid 39299326)
19. GIROUX M, HWANG P, PRASAD A: Controlled particle dispersion: applying vortical flow to optimize nasal drug deposition. Drug Delivery Technology (2005) 5(3):44-49.
20. SCHIPPER NG, VERHOEF JC, MERKUS FW: The nasal mucocilliary clearance: relevance to nasal drug delivery. Pharm. Res. (1991) 8:807-814.
21. CHIEN YW, CHANG SF: Intranasal drug delivery for systemic medication. Crit. Rev. Ther. Drug Carrier Syst. (1987) 4:67-194. (Pubitemid 18042038)
22. HEHAR SS, MASON JD, STEPHEN AB, WASHINGTON N, JONES NS, JACKSON SJ et al.: Twenty four hour ambulatory nasal pH monitoring. Clin. Otolaryngol. (1999) 24:24-25. (Pubitemid 29116473)
23. CHIEN YW: Biopharmaceutics basis for transmucosal delivery. STP Pharma. Sci (1995) 5:718.
24. CHIEN YW: Nasal Systemic Drug Delivery. YW Chien, KS Su, S Chang (Eds), Marcel Dekker, New York, NY, USA (1989):1-38.
25. NOBLE RE: Effect of environmental contaminants on nasal lysozyme secretions. Sci. Total Environ. (2002) 284(1-3):263-266. (Pubitemid 34061860)
26. BROWNING S, HOUSLEY D, RICHARDS R, ECCLES R: The effects of oxymetazoline on lysozyme secretion from the human nasal mucosa. Acta Otolaryngol. (1997) 117(6):851-855. (Pubitemid 27521363)
27. REED CJ: Drug metabolism in the nasal cavity: relevance to toxicology. Drug Metab. Rev. (1993) 25:173-205. (Pubitemid 23084975)
28. DAHL AR, LEWIS JL: Respiratory tract uptake of inhalants and metabolism of xenobiotics. Ann. Rev Pharmacol. Toxicol. (1993) 32:383-407. (Pubitemid 23116012)
29. THORNTON-MANNING JR, DAHL AR: Metabolic capicity of nasal tissue interspecies comparisons of xenobiotic- metabolizing enzymes. Mutat. Res. (1997) 380:43-59. (Pubitemid 27475251)
30. LEWIS JL, NIKULA KJ, NOVAK R, DAHL AR: Comparative localization of carboxylesterase in F344 rat, beagle dog and human nasal tissue. Anat. Rec. (1994) 239:55-64. (Pubitemid 24123299)
31. ACETO A, LLIO CD, ANGELUCCI S, LONGO V, GERVASI PG, FEDERICI G: Glutathione transferases in human nasal mucosa. Arch. Toxicol. (1989) 63:427-431. (Pubitemid 19269657)
32. KRISHNA NS, GETCHELL TV, AWASTHI YC, GATECHELL ML, DHOOPER N: Age and gender-related trends in the expression of glutathione S-transferases in human nasal mucosa. Ann. Otol. Rhinol. Laryngol. (1995) 104:812-822.
33. SARKAR MA: Drug metabolism in the nasal mucosa. Pharm. Res. (1992) 9(1):1-9.
34. ILLUM LE: Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int. J. Pharmaceut. (2001) 109:222.
35. DONDETI P, ZIA H, NEEDHAM TE: Bioadhesive and formulation parameters affecting nasal absorption. Int. J. Pharmaceut. (1996) 27:115. (Pubitemid 26092131)
36. SCHIPPER NG, VARUM KM, STENBERG P, OCKLIND G, LENNERNAS H, ARTURSSON P: Chitosans as absorption enhancers of poorly absorbable drugs. 3. Influence of mucus on absorption enhancement. Eur. J. Pharmaceut. Sci. (1999) 8:335. (Pubitemid 29325026)
37. LIM ST, MARTIN GP, BERRY DJ, BROWN MB: Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. J. Control. Release (2000) 66:281. (Pubitemid 30160864)
38. UGWOKE MI, VERBEKE N, KINGET R: The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. (2001) 53:3. (Pubitemid 32140298)
39. EDSMAN K, HAGERSTROM H: Pharmaceutical applications of mucoadhesion for the non-oral routes. J. Pharm. Pharmacol. (2005) 57:3. (Pubitemid 40030097)
40. PILLION DJ, ATCHISON JA, GARGIULO C, WANG RX, WANG P, MEEZAN E: Insulin delivery in nosedrops: new formulations containing alkylglycosides. Endocrinology (1994) 135:1386-1391. (Pubitemid 24377392)
41. PILLION DJ, WANG P, YORKS J, MCCANN P, MEEZAN E: Systemic absorption of insulin and glucagon applied topically to the eye of rats and a diabetic dog. J. Ocul. Pharmacol. (1995) 2:283-295.
42. AHSAN F, ARNOLD JJ, YANG T, MEEZAN E, SCHWIEBERT EM, PILLION DJ: Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-β-17 cyclodextrin, on insulin movement across human bronchial epithelial cells 16HBE14o(-). Eur. J. Pharm. Sci. (2003) 20:27-34. (Pubitemid 37103229)
43. YANG T, MUSTAFA F, BAI S, AHSAN F: Pulmonary delivery of low molecular weight heparins. J. Drug Targeting (2005) 13:29-38.
44. ARNOLD JJ, AHSAN F, MEEZAN E, PILLION DJ: Nasal administration of low molecular weight heparin. J. Pharm. Sci. (2002) 91:1707-1714. (Pubitemid 34680234)
45. WEBER N, BENNING H: Metabolism of orally administered alkyl glycosides. J. Nutr. (1984) 114:246-254.
46. HOVGAARD L, JACOBS H, MAZER NA, KIM SW: Stabilization of insulin by alkylmaltosides. A. Spectroscopic evaluation. Int. J. Pharm. (1996) 132:107-113. (Pubitemid 26160306)
47. MAGGIO ET: Recent developments in intranasal drug delivery technology are creating new vistas for peptide and protein therapeutics. In: Drug Delivery Companies Report (2005):29-33.
48. CHEN S-C, EITING KT, LI AA, LAMHARZI N, QUAY SC: Peptide drug permeation enhancement by select classes of lipids. 45th American Society for Cell Biology Meeting, San Francisco, CA, USA (2005). Abstract.
49. MARPLE B, ROLAND P, BENNINGER M: Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol. Head Neck Surg. (2004) 130(1):131-141. •• This paper provides an excellent review of in vitro versus in vivo prediction of nasal toxicity. It presents the remarkable, but well-documented, findings highlighting the nearly complete lack of correlation of in vitro and in vivo assessment of nasal toxicity - a very important and relevant issue facing scientists in this field.
50. KLOSSEK JM, LALIBERTE F, LALIBERTE MF et al.: Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long term treatment of perennial allergic rhinitis. Rhinology (2001) 39:17-22. (Pubitemid 32321967)
51. AINGE G, BOWLES JA, MCCORMICK SG et al.: Lack of deleterious effects of corticosteroid sprays containing benzalkonium chloride on nasal ciliated epithelium. Drug Invest. (1994) 8:127-133.
52. HOLM AF, FOKKENS WJ, GODTHELP T et al.: A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study. Clin. Otolaryngol. (1998) 23:69-73. (Pubitemid 28344941)
53. MCMAHON C, DARBY Y, RYAN R et al.: Immediate and short-term effects of benzalkonium chloride on the human nasal mucosa in vivo. Clin. Otolaryngol. (1997) 22:318-322. (Pubitemid 28346968)
54. BRAAT JP, AINGE G, BOWLES JA et al.: The lack of effect of benzalkonium chloride on the cilia of the nasal mucosa in patients with perennial allergic rhinitis: a combined functional, light, scanning and transmission electron microscopy study. Clin. Exp. Allergy (1995) 25:957-965.
55. GRAF P, ENERDAL J, HALLEN H: Ten days' use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis. Arch. Otolaryngol. Head Neck Surg. (1999) 125:1128-1132. (Pubitemid 29473377)
56. BERG OH, HENRIKSEN RN, STEINSVAG SK: The effect of a benzalkonium chloride-containing nasal spray on human respiratory mucosa in vitro as a function of concentration and time of action. Pharmacol. Toxicol. (1995) 76:245-249.
57. LANGE B, LUKAT KF, BACHERT C: Local tolerability of a benzalkonium chloride-containing homeopathic nasal spray. Allergologie (2004) 27(3):102. (Pubitemid 38418020)
58. RIECHELMANN H, DEUTSCHLE T, STUHLMILLER A, GRONAU S, BURNER H: Nasal toxicity of benzalkonium chloride. Am. J. Rhinol. (2004) 18(5):291-299. (Pubitemid 39618659)